Kwality Pharmaceutical has raised its FY27 guidance, with revenue now projected at over 700 Cr, EBITDA between 189-196+ Cr, and PAT exceeding 109 Cr, driven by strong execution and market visibility.

The financial results for the quarter saw revenue of 162.4 Cr, EBITDA of 41 Cr, and a profit after tax of 25.7 Cr.

Strategic expansion into high-entry-barrier specialty products, including new biologics and hormone manufacturing facilities, is underway.

New market registrations and regulatory certifications are expanding access to global markets, while R&D in biosimilars and oncology progresses.